Related Experiment Video
Updated: Apr 19, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Predicting primary resistance to third-generation EGFR-TKIs in lung adenocarcinoma using a multisource cross-modal
Yunfan Wang1, Ke Min1, Li Tao2
1Department of Oncology, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, China.
None:
The aim of this study was to investigate the utility of a multisource cross-modal Transformer (MC-Trans) model in predicting primary resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitors (3rd-EGFR-TKIs) in patients with lung adenocarcinoma. A retrospective analysis of clinical and imaging data from 222 lung adenocarcinoma patients treated with 3rd-EGFR-TKIs was conducted. Patients were allocated to a training/validation cohort (n = 136) and two external test cohorts (n = 34 and n = 52). The Table Transformer and a Swin Transformer-based model were employed to extract features from tabular and CT imaging data, respectively, to construct the MC-Trans model. The results demonstrated that MC-Trans exhibited excellent performance in predicting primary resistance, with an ROC-AUC of 0.89, which was significantly superior to those of the unimodal models (tabular model: 0.78; CT model: 0.63). Furthermore, predictions on external Test Cohort 2 revealed that the predictive performance of MC-Trans was comparable to that of a human expert panel. The study also revealed that MC-Trans could predict the risk of disease progression even among patients without primary resistance. In conclusion, MC-Trans may serve as a valuable tool to assist in determining the therapeutic response of lung adenocarcinoma patients to 3rd-EGFR-TKIs. Keywords: Artificial intelligence; Lung Cancer; Multimodal models; Third-generation EGFR-TKIs; Primary Resistance.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Treatment Resistant Cancers
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistent Cancers